Recerca

Sarcomes i Histiocitosis

Buscador de publicacions

Publicacions

  • Gorostegui M, Muñoz JP, Pérez-Jaume S, Simao-Rafael M, Cristina Larrosa Espinosa, Garraus-Oneca M, Salvador-Marcos N, Lavarino C, Krauel L, Mañe S, Castañeda-Heredia A and Mora J.

    Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy

    Cancers . 16(9): . Nº de cites: 1

    [doi:10.3390/cancers16091735]

  • Pasten A, Salvador-Alarcon C, Mora J, Martín Gimenez MP, Carrasco-Torrents R and Krauel L.

    Current Status of Fertility Preservation in Pediatric Oncology Patients.

    CHILDREN-BASEL . 11(5): . Nº de cites: 1

    [doi:10.3390/children11050537]

  • Mora J, Modak S, Kinsey J, Ragsdale CE and Lazarus HM.

    GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma

    INTERNATIONAL JOURNAL OF CANCER . 154(8): 1340-1364. Nº de cites: 5

    [doi:10.1002/ijc.34815]

  • Llurba E, Fàtima Crispi Brillas, Crovetto F, Youssef L, Delgado JL, Puig I, Mora J, Krofta L, Mackova K, Martinez-Varea A, Tubau A, Ruiz-Llobet A, Paya A, Prat M, Chantraine F, Comas C, Kajdy A, Lopez-Tinajero MF, Figueras-Retuerta F and Gratacós E.

    Multicentre randomised trial of screening with sFlt1/PlGF and planned delivery to prevent pre-eclampsia at term: protocol of the PE37 study.

    BMJ Open . 14(3): . Nº de cites: 1

    [doi:10.1136/bmjopen-2023-076201]

  • Villasante A, Corominas J, Alcon C, Garcia-Lizarribar A, Mora J, Lopez-Fanarraga M and Samitier J.

    Identification of GB3 as a Novel Biomarker of Tumor-Derived Vasculature in Neuroblastoma Using a Stiffness-Based Model

    Cancers . 16(5): . Nº de cites: 1

    [doi:10.3390/cancers16051060]

  • Chantada L, Gorostegui M, Lowe J, Ranasinghe N, Villegas L, Geel J, Howard S, Bouffet E, Chantada G, Challinor J and Cappellano A.

    SIOP pediatric oncology services Global Mapping Program: Latin American data collection

    PEDIATRIC BLOOD & CANCER . 71(2): . Nº de cites: 2

    [doi:10.1002/pbc.30796]

  • Valls-Esteve A, Tejo-Otero A, Adell NE, Lustig-Gainza P, Fenollosa-Artés F, Buj-Corral I, Rubio-Palau J, Munuera-del Cerro JL and Krauel L.

    Advanced Strategies for the Fabrication of Multi-Material Anatomical Models of Complex Pediatric Oncologic Cases

    BIOENGINEERING-BASEL . 11(1): . Nº de cites: 2

    [doi:10.3390/bioengineering11010031]

  • Aschero MR, Ganiewich D, Lamas G, Restrepo-Perdomo CA, Ottaviani D, Zugbi S, Camarero S, Néspoli E, Cuadrado-Vilanova M, Pérez-Jaume S, Pascual-Pastó G, Sampor C, Grigorovski N, Salas B, Suñol M, Carcaboso AM, Mora J, de Dávila MTG, Doz F, Radvanyi F, Abramson DH, Llera AS, Schaiquevich PS, Lubieniecki F and Chantada G.

    Immunohistochemical expression of TFF1 is a marker of poor prognosis in retinoblastoma

    PEDIATRIC BLOOD & CANCER . 71(1): . Nº de cites: 1

    [doi:10.1002/pbc.30717]

  • Simao-Rafael M, Cruz-Martínez O, Pérez-Jaume S, Santa-María López V, Lavarino C, Salvador-Hernandez H, Muchart-Lopez J, Hinojosa J, Suñol M and Morales-La Madrid A.

    Use of bevacizumab in pediatric low-grade glioma: Ten-year experience in a single center

    EJC Paediatric Oncology . 2: 100115.

    [doi:10.1016/j.ejcped.2023.100115]

  • Ana Carolina Izurieta Pacheco, Sangrós-Gimenez A, Martínez-Garcia E, Pérez-Jaume S, Mora J and Gorostegui-Obanos M.

    Vitamin D Status in Children With High-risk Neuroblastoma

    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY . 45(8): 953-958. Nº de cites: 2

    [doi:10.1097/MPH.0000000000002762]